Gracell Biotechnologies to Participate in Citi 2022 Virtual Immuno-Oncology Summit

Rhea-AI Summary

Gracell Biotechnologies Inc. (NASDAQ: GRCL) will participate in the Citi 2022 Immuno-Oncology Summit on February 16, 2022. Dr. William Cao, the company's Founder and CEO, will engage in a fireside chat from 3:30 PM to 4:30 PM ET. A webcast of the discussion will be accessible on Gracell's Investors webpage, with a replay available for 180 days post-event. Gracell focuses on developing advanced cell therapies for cancer treatment, utilizing its unique technology platforms to improve therapy quality, reduce costs, and enhance effectiveness against solid tumors.

SUZHOU, China and PALO ALTO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Citi 2022 Immuno-Oncology Summit on February 16^th.

Dr. William Cao, Founder, Chairman and CEO of Gracell will participate in a fireside chat at 3:30pm - 4:30pm Eastern Time, February 16^th.

A webcast of the fireside chat will be available on the “Events and Presentations” page of the Investors section of the Company's website. A replay of the webcast will be available for 180 days following the event. For more information, please visit ir.gracellbio.com.

About Gracell

Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR, TruUCAR and SMART CART™ technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong
gracie.tong@gracellbio.com

FAQ

What is Gracell's participation in the Citi 2022 Immuno-Oncology Summit on February 16, 2022?

Gracell Biotechnologies Inc. will participate in the Citi 2022 Immuno-Oncology Summit on February 16, 2022.

Who will represent Gracell at the Citi Immuno-Oncology Summit?

Dr. William Cao, the Founder and CEO of Gracell, will represent the company.

What time is Gracell's fireside chat during the Citi 2022 Immuno-Oncology Summit?

The fireside chat is scheduled from 3:30 PM to 4:30 PM Eastern Time.

How can I watch the Gracell fireside chat from the Citi Summit?

The fireside chat will be webcasted on Gracell's Investors page, with a replay available for 180 days.

What technologies does Gracell use in its cell therapies?

Gracell utilizes its FasTCAR, TruUCAR, and SMART CART™ technology platforms to develop its therapies.